Vident Advisory, LLC Beam Therapeutics Inc. Transaction History
Vident Advisory, LLC
- $3.62 Trillion
- Q2 2024
A detailed history of Vident Advisory, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 18,453 shares of BEAM stock, worth $431,800. This represents 0.01% of its overall portfolio holdings.
Number of Shares
18,453
Previous 19,400
4.88%
Holding current value
$431,800
Previous $641 Million
32.55%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding BEAM
# of Institutions
230Shares Held
73.6MCall Options Held
283KPut Options Held
233K-
Farallon Capital Management LLC San Francisco, CA7.91MShares$185 Million0.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$185 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$179 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.63MShares$178 Million1.63% of portfolio
-
Arch Venture Management, LLC Chicago, IL5.44MShares$127 Million74.72% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.65B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...